Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Clinical-stage biotech developing small molecule and biologic therapies for cancer and autoimmune diseases, focused on novel mechanisms.
GenFleet Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, that develops small molecule and biologic therapies for the treatment of cancer and autoimmune diseases. The organization utilizes a proprietary discovery platform to advance a development pipeline consisting of more than ten product candidates, with several currently undergoing clinical trials and targeting commercialization within the next three to five years. To support its research and clinical operations, the enterprise has secured significant venture capital financing, including a $57.7 million Series B round in early 2020 and a $75 million Series C round in December 2021. These funding rounds were backed by a syndicate of prominent institutional investors such as Huagai Capital, Northern Light Venture Capital, Baidu Ventures, and CDH Investments. GenFleet Therapeutics was originally founded in August 2017 by co-founders Jiong Lan and Qiang Lu.
GenFleet Therapeutics has raised $96.0M across 2 funding rounds.
GenFleet Therapeutics has raised $96.0M in total across 2 funding rounds.
GenFleet Therapeutics has raised $96.0M across 2 funding rounds. Most recently, it raised $78.5M Series C in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2022 | $78.5M Series C | Zeng Zhiqiang | Baidu Ventures, CDH Investments, Cherami Investment Group, Dyee Capital, HM Capital, Lake Bleu Capital, Panlin Capital, Qiaojing Eastern Investment, Shanjin Asset, Suxin Venture Capital | Announced |
| Dec 30, 2018 | $17.5M Series A | Ally Bridge Group | CSPC Pharma, Hidragon Capital, Sinopharm Capital, TF Capital | Announced |
GenFleet Therapeutics has raised $96.0M in total across 2 funding rounds.
GenFleet Therapeutics's investors include Zeng Zhiqiang, Baidu Ventures, CDH Investments, Cherami Investment Group, Dyee Capital, HM Capital, Lake Bleu Capital, Panlin Capital, Qiaojing Eastern Investment, Shanjin Asset, Suxin Venture Capital, Ally Bridge Group.